Pure Global
NCT05727891

Evaluation of Tonabersat for DME

A Phase 2 Evaluation of Tonabersat for Diabetic Macular Edema (Protocol AN)
Jaeb Center for Health Research·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Diabetic Macular Edema
Drug/Device/Intervention
Tonabersat
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Jaeb Center for Health Research
Timeline & enrollment
Phase
Phase 2
Start date
Mar 01, 2023
End date
Mar 01, 2025
Enrollment
128 participants
Primary outcome

Mean change in central subfield thickness

Summary

This randomized clinical trial will evaluate the effect of tonabersat compared with placebo
 on central subfield thickness (CST) in eyes with center-involved diabetic macular edema
 (CI-DME) and good visual acuity.

ICD-10 classifications
Diabetic retinopathyOther specified diabetes mellitus with ophthalmic complicationsUnspecified diabetes mellitus with ophthalmic complicationsDiabetic cataractType 2 diabetes mellitus with ophthalmic complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05727891
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05727891 through Pure Global AI's free database. This Phase 2 trial is sponsored by Jaeb Center for Health Research and is currently Not yet recruiting. The study focuses on Diabetic Macular Edema. Target enrollment is 128 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.